Companion Diagnostics Industry Statistics

In this post, we will explore key statistics and trends shaping the companion diagnostics industry. From the dominance of the U.S in the market to the projected growth in Next-generation Sequencing technology and specific therapeutic areas driving demand, these insights offer a comprehensive overview of the current landscape and future prospects in this sector.

Statistic 1

"The U.S accounted for the largest share of the companion diagnostics market in 2020."

Statistic 2

"In terms of technology, Polymerase Chain Reaction-based tests held the largest share of the market in 2021."

Statistic 3

"It is projected that the Next-generation Sequencing (NGS) segment will have the fastest growth during the forecast period."

Statistic 4

"The growth of the market is primarily driven by the increasing demand for targeted therapies."

Statistic 5

"Lung cancer is expected to be the most prominent indication till 2025."

Statistic 6

"The lung cancer segment accounted for more than 30% of the market share in 2019."

Statistic 7

"At the end of 2023, Asia-Pacific companion diagnostics market is predicted to have the 2nd largest share."

Statistic 8

"Roche Diagnostics is the leading company in the global market."

Statistic 9

"The LATAM market is expected to grow from $202M in 2020 to $491M in 2025, at a CAGR of 19.4%."

Statistic 10

"The breast cancer segment was valued at $876M in 2017."

Statistic 11

"By the end of 2026, Immunochemistry testing is predicted to surpass $575M."

Statistic 12

"The global market for Neurological diseases diagnostics is expected to reach $392M by 2026."

Statistic 13

"It's estimated that 79 FDA-approved therapies have at least one approved companion diagnostic."

Statistic 14

"Therapeutic areas like oncology dominate the use of companion diagnostics."

Statistic 15

"As a single country, the US is anticipated to control a 46% share of the market in 2026."

In conclusion, the companion diagnostics industry is experiencing significant growth driven by an increasing demand for targeted therapies, with the U.S. leading the market in both market share and FDA-approved therapies. Key technologies such as Polymerase Chain Reaction-based tests and Next-generation Sequencing are playing pivotal roles, particularly in the oncology space, where lung cancer remains a prominent indication. Companies like Roche Diagnostics are at the forefront of this global market, with regions like Asia-Pacific and LATAM showing substantial growth potential. As we look toward the future, the industry is poised for continued expansion, especially in areas such as breast cancer, immunochemistry testing, and neurological diseases diagnostics, shaping the landscape for precision medicine.